Genmab — April 2018

[Helge_LarsenPI-redaktør]

Udbudspriser har ikke været stillet i længere tid.

[E_L]

https://www.dagensmedicin.se/artiklar/2018/04/19/avtal-om-efterlangtat-myelomlakemedel/ Sweden

[rex_pacis]

langt fremskreden...

[Bulder]

Who have we left now in mono? Holland?

[rex_pacis]

I used to be UK, Sweden and Holland; and now UK and Sweden are buying, so I guess Holland will be the last

[E_L]

Sweden is still only mono if i read this correct?

[Bulder]

yes, mono only - same same as UK

[Bulder]

Denmark is on its way. Mono is ok and they have made a draft for 2. line combo. Wil assumably be soc soon. http://www.medicinraadet.dk/media/5467/indstilling-10-behandlingsvejledning-knoglemarvskraeft-myelomatose.pdf

[Bulder]

Here is the draft protocol page 8 http://www.medicinraadet.dk/media/6275/protokol-10-knoglemarvskraeft.pdf

[bibob]

Seems like we are holding in strong hands. But watch, !! - when they release the short positions the bullit is going much stronger and faster than you can buy it for now. - maybe it still falls a bit , But there is no more downside as I see it. Good luck.

[henrik48]

Vi er alle enige med dig, bibob....i dag har vi “Malaga”-vejr

[GeorgeBest]

Ny duobody i klinikken. På side 13 i vedlagte slideshow fra GF anføres JNJ-64407564. Den har ikke tidligere været nævnt! http://files.shareholder.com/downloads/AMDA-KPIBN/138540251x7895654x976323/FA28BE7E-0E02-4A37-8E24-39ACD8F23226/AGM_2018_vfinal_website.pdf

[GeorgeBest]

JNJ-64407564 fra CT https://clinicaltrials.gov/ct2/results?cond=JNJ-64407564&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=

[GeorgeBest]

Den må give en lille milepæl når første patienter doseres

[Bulder]

Blev linket af gentogen 23/1 kl 16.37

[GeorgeBest]

hold da op Bulder, dig kan man ikke kører om hjørner med Men det jeg mente var at den er ny i Gnemabs slideshow. Var f.eks. ikke med i slideshow
efter årsregnskabet!

[Bulder]

Novod: The new DuoBody has the name JNJ-7564 and it started ph I in March 2018. Besides this being a potentially new and interesting myeloma drug over time, we believe it is also positive that JnJ is expanding its Genmab myeloma commitment beyond Darzalex.

[Bulder]

Han har forsøgt at lokke ud af JnJ-folkene hvad det andet target er (od over cd3), men de vil ikke afsløre det.

[Bulder]

ud over

[Bulder]

Han gætter selv på en receptor der hedder GPRC5D.